Cargando…
Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?
OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumour associated with poor 5-year survival. We aimed to determine factors which differentiate short and long-term survivors and identify a prognostic biomarker. METHODS: Over a ten-year period, patients with resected PDAC who devel...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366827/ https://www.ncbi.nlm.nih.gov/pubmed/30774772 http://dx.doi.org/10.18632/oncotarget.26511 |
_version_ | 1783393672566407168 |
---|---|
author | Gall, Tamara M.H. Gerrard, Gareth Frampton, Adam E. Castellano, Leandro Ahmad, Raida Habib, Nagy Spalding, Duncan Pai, Madhava Foroni, Letizia Jiao, Long R. |
author_facet | Gall, Tamara M.H. Gerrard, Gareth Frampton, Adam E. Castellano, Leandro Ahmad, Raida Habib, Nagy Spalding, Duncan Pai, Madhava Foroni, Letizia Jiao, Long R. |
author_sort | Gall, Tamara M.H. |
collection | PubMed |
description | OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumour associated with poor 5-year survival. We aimed to determine factors which differentiate short and long-term survivors and identify a prognostic biomarker. METHODS: Over a ten-year period, patients with resected PDAC who developed disease recurrence within 12 months (Group I) and those who had no disease recurrence for 24 months (Group II) were identified. Clinicopathological data was analysed. Ion Torrent high-throughput sequencing on DNA extracted from FFPE tumour samples was used to identify mutations. Additionally, peripheral blood samples were analysed for variants in cell-free DNA, circulating tumour cells (CTCs), and microRNAs. RESULTS: Multivariable analysis of clinicopathological factors showed that a positive medial resection margin was significantly associated with short disease-free survival (p = 0.007). Group I patients (n = 21) had a higher frequency of the KRAS mutant mean variant allele (16.93% ± 11.04) compared to those in Group II (n = 13; 7.55% ± 5.76, p = 0.0078). Group I patients also trended towards having a KRAS c.35G>A p.Gly12Asp mutation in addition to variants in other genes, such as TP53, CDKN2A, and SMAD4. Mutational status of cell-free DNA, and number of CTCs, was not found to be useful in this study. A circulating miRNA (hsa-miR-548ah-5p) was found to be significantly differentially expressed. CONCLUSIONS: Medial resection margin status and the frequency of KRAS mutation in the tumour tissue are independent prognostic indicators for resectable PDAC. Circulating miRNA hsa-miR-548ah-5p has the potential to be used as a prognostic biomarker. |
format | Online Article Text |
id | pubmed-6366827 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-63668272019-02-15 Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? Gall, Tamara M.H. Gerrard, Gareth Frampton, Adam E. Castellano, Leandro Ahmad, Raida Habib, Nagy Spalding, Duncan Pai, Madhava Foroni, Letizia Jiao, Long R. Oncotarget Research Paper OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumour associated with poor 5-year survival. We aimed to determine factors which differentiate short and long-term survivors and identify a prognostic biomarker. METHODS: Over a ten-year period, patients with resected PDAC who developed disease recurrence within 12 months (Group I) and those who had no disease recurrence for 24 months (Group II) were identified. Clinicopathological data was analysed. Ion Torrent high-throughput sequencing on DNA extracted from FFPE tumour samples was used to identify mutations. Additionally, peripheral blood samples were analysed for variants in cell-free DNA, circulating tumour cells (CTCs), and microRNAs. RESULTS: Multivariable analysis of clinicopathological factors showed that a positive medial resection margin was significantly associated with short disease-free survival (p = 0.007). Group I patients (n = 21) had a higher frequency of the KRAS mutant mean variant allele (16.93% ± 11.04) compared to those in Group II (n = 13; 7.55% ± 5.76, p = 0.0078). Group I patients also trended towards having a KRAS c.35G>A p.Gly12Asp mutation in addition to variants in other genes, such as TP53, CDKN2A, and SMAD4. Mutational status of cell-free DNA, and number of CTCs, was not found to be useful in this study. A circulating miRNA (hsa-miR-548ah-5p) was found to be significantly differentially expressed. CONCLUSIONS: Medial resection margin status and the frequency of KRAS mutation in the tumour tissue are independent prognostic indicators for resectable PDAC. Circulating miRNA hsa-miR-548ah-5p has the potential to be used as a prognostic biomarker. Impact Journals LLC 2019-01-22 /pmc/articles/PMC6366827/ /pubmed/30774772 http://dx.doi.org/10.18632/oncotarget.26511 Text en Copyright: © 2019 Gall et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Gall, Tamara M.H. Gerrard, Gareth Frampton, Adam E. Castellano, Leandro Ahmad, Raida Habib, Nagy Spalding, Duncan Pai, Madhava Foroni, Letizia Jiao, Long R. Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? |
title | Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? |
title_full | Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? |
title_fullStr | Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? |
title_full_unstemmed | Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? |
title_short | Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? |
title_sort | can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366827/ https://www.ncbi.nlm.nih.gov/pubmed/30774772 http://dx.doi.org/10.18632/oncotarget.26511 |
work_keys_str_mv | AT galltamaramh canwepredictlongtermsurvivalinresectablepancreaticductaladenocarcinoma AT gerrardgareth canwepredictlongtermsurvivalinresectablepancreaticductaladenocarcinoma AT framptonadame canwepredictlongtermsurvivalinresectablepancreaticductaladenocarcinoma AT castellanoleandro canwepredictlongtermsurvivalinresectablepancreaticductaladenocarcinoma AT ahmadraida canwepredictlongtermsurvivalinresectablepancreaticductaladenocarcinoma AT habibnagy canwepredictlongtermsurvivalinresectablepancreaticductaladenocarcinoma AT spaldingduncan canwepredictlongtermsurvivalinresectablepancreaticductaladenocarcinoma AT paimadhava canwepredictlongtermsurvivalinresectablepancreaticductaladenocarcinoma AT foroniletizia canwepredictlongtermsurvivalinresectablepancreaticductaladenocarcinoma AT jiaolongr canwepredictlongtermsurvivalinresectablepancreaticductaladenocarcinoma |